Human genomics technologies in clinical studies – the research landscape: report on the 1990–2024 period

1:1
Published on 14 December, this WHO technical document maps global trends in registered clinical studies using human genomic technologies from 1990 to 2024, including patterns of inclusion and equity.

This WHO snapshot provides a global overview of clinical studies involving human genomic technologies registered between 1990 and 2024. It summarises how research activity has evolved over time and examines patterns in growth, disease focus, geographical distribution and population inclusion, with specific attention to equity of participation. The report is intended to inform stakeholders about the current landscape of genomics in clinical research and where gaps or imbalances may remain.

Acces this publication (pdf)
Scientific paper

Year of publication

2025

Source

World Health Organization (WHO) (Technical document; WHO Team: Research for Health (RFH))

Link to cite

Acces to Link >

Author

WHO Team: Research for Health (RFH)

You might also be interested in

European Parliament

European Parliament draft report urges a binding EU rare disease action framework

A legislative own initiative file in the Parliament’s new public health committee sets out what an EU “rare disease action framework” could look like — and why it could change how Europe measures progress for patients.
Woman helping out a person with a disease

Women’s Day highlights widening gender inequalities in rare diseases

Drawing on Europe-wide patient and carer surveys, ERDERA highlights how gender can shape diagnostic delays, care burden and the evidence base for rare-disease research.
European Parliament Photograph

New European Parliament study maps options for an EU rare disease action plan

European Parliament research service assessment, published in February 2026, identifies 31 measures that could form an EU rare disease action plan, highlighting European Reference Networks and cross-border collaboration including ERDERA as drivers of EU added value.
Publicaciones (1)

EU rare disease action plan- European Added Value Assessment

This study investigates possible measures that could be taken at EU level to address these challenges. It finds significant European added value in harmonising coordination and access across the 27 Member States, mainly in terms of improved diagnostic tools and availability of medical treatment, better health outcomes, particularly lower infant mortality, and improved well-being of family members and caregivers.

ERDERA's

search form